BREAKWATER: Randomized phase 3 study of encorafenib (enco) cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).

Scott Kopetz,Axel Grothey,Rona Yaeger,Fortunato Ciardiello,Jayesh Desai,Tae Won Kim,Tim Maughan,Eric Van Cutsem,Harpreet Wasan,Takayuki Yoshino,Michelle L. Edwards,Adele Golden,Ashwin Gollerkeri,Josep Tabernero

Journal of Clinical Oncology（2021）

Cited 13|Views5

No score

Abstract

TPS3619Background: Approximately 10% of patients (pts) with mCRC have BRAF mutations (mostly V600E). 1L tx options for BRAFV600E mCRC are limited to cytotoxic chemotherapy ± anti-VEGF or anti-EGFR,...

Translated text

Key words

colorectal cancer,chemotherapy,encorafenib,cetuximab,first-line,e-mutant

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined